Company Analysis
Sign in

AIM ImmunoTech Inc. (AIM)

NYSE: AIM · Biological Products, (No Diagnostic Substances) · Ocala, FL · filing with the SEC since 1996
Full chart Alerts Compare
Grade3.3
◀ Past 2.6● Present 3.7▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AIM ImmunoTech Inc.’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 3 in 2023
Applications published
28
since 2001, to Dec 31, 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'07'08'09'10'11'12'14'15'16'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
HEMISPHERX BIOPHARMA, INC. a former name
US, as the owner printed on each patent
10 granted
14 published
AIM ImmunoTech Inc. its own name
US, as the owner printed on each patent
5 granted
13 published
HEMISPHERx BIOPHARMA, INC. a former name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 27, 202512,312,376Therapeutic double stranded RNA and methods for producing the sameBiotechnologyAIM ImmunoTech Inc.
Oct 1, 202412,102,649Methods and compositions for treating endometriosisPharmaceuticalsAIM ImmunoTech Inc.
Nov 14, 202311,813,281Methods for improving exercise tolerance in myalgic encephalomyelitis patientsPharmaceuticalsAIM ImmunoTech Inc.
Nov 14, 202311,813,279Compositions for cancer therapy and methodsPharmaceuticalsAIM ImmunoTech Inc.
May 9, 202311,642,396Method of reducing antigenic drift or reassortment of viruses in a host animal using α interferonPharmaceuticalsAIM ImmunoTech Inc.
Apr 19, 20169,315,538Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activityPharmaceuticalsHEMISPHERX BIOPHARMA, INC.
May 13, 20148,722,874Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activityPharmaceuticalsHEMISPHERX BIOPHARMA, INC.
Dec 13, 20118,075,878Broad spectrum immune and antiviral gene modulation by oral interferonPharmaceuticalsHEMISPHERX BIOPHARMA, INC.
Dec 13, 20118,075,877Broad spectrum immune and antiviral gene modulation by oral interferonPharmaceuticalsHEMISPHERX BIOPHARMA, INC.
May 17, 20117,943,147dsRNAs as influenza virus vaccine adjuvants or immuno-stimulantsPharmaceuticalsHEMISPHERX BIOPHARMA, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 14, 20242024/0376481COMPOSITIONS AND METHODS FOR ENHANCING AND EXPANDING INFECTION INDUCED IMMUNITYPharmaceuticalsAIM ImmunoTech Inc.
Oct 24, 20242024/0350527COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUEPharmaceuticalsAIM ImmunoTech Inc.
Jul 4, 20242024/0218373METHODS AND COMPOSITIONS FOR TREATING NEUROINFLAMMATIONPharmaceuticalsAIM ImmunoTech Inc.
Dec 8, 20222022/0389050THERAPEUTIC DOUBLE STRANDED RNA AND METHODS FOR PRODUCING THE SAMEBiotechnologyAIM ImmunoTech Inc. · patent 12,312,376 granted from it
Dec 8, 20222022/0387475METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSISPharmaceuticalsAIM ImmunoTech Inc. · patent 12,102,649 granted from it
Dec 8, 20222022/0387472COMPOSITIONS AND METHODS FOR TREATING CANCERPharmaceuticalsAIM ImmunoTech Inc.
Dec 1, 20222022/0380769METHODS, COMPOSITIONS, AND VACCINES FOR TREATING A VIRUS INFECTIONPharmaceuticalsAIM ImmunoTech Inc.
Nov 10, 20222022/0356476COMPOSITIONS AND METHODS USEFUL FOR EBOLA VIRUS INFECTIONPharmaceuticalsAIM ImmunoTech Inc.
Sep 8, 20222022/0280547COMPOSITIONS AND METHODS FOR TREATING LONG COVIDPharmaceuticalsAIM ImmunoTech Inc.
Mar 31, 20222022/0096518COMPOSITIONS AND METHODS FOR CANCER THERAPYPharmaceuticalsAIM ImmunoTech Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AIM · research, not advice